Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner

References

• MacBride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc 2010;85:87–94
   PubMed Web of Science ®Google Scholar
• Beers MH, Porter RS, Jones TV, Kaplan JL, Berkwits M. Gynecology and obstetrics. In The Merck Manual of Diagnosis and Therapy, 17th edn. Whitehouse Station, NJ: Merck Research Laboratories. Accessed December 12, 2006
   Google Scholar
• Nappi RE, Lachowsky M. Menopause and sexuality: prevalence of symptoms and impact on quality of life. Maturitas 2009;63:138–41
   PubMed Web of Science ®Google Scholar
• Bachmann GA, Leiblum SR. Sexuality in sexagenarian women. Maturitas 1991;13:43–50
   PubMed Web of Science ®Google Scholar
• Pandit L, Ouslander JG. Postmenopausal vaginal atrophy and atrophic vaginitis. Am J Med Sci 1997;314:228–31
   PubMed Web of Science ®Google Scholar
• Milsom I, Arvidsson L, Ekelund P, Molander U, Eriksson O. Factors influencing vaginal cytology, pH and bacterial flora in elderly women. Acta Obstet Gynecol Scand 1993;72:286–91
   PubMed Web of Science ®Google Scholar
• Palacios S. Managing urogenital atrophy. Maturitas 2009;63:315–18
   PubMed Web of Science ®Google Scholar
• Stika CS. Atrophic vaginitis. Dermatol Ther 2010;23:514–22
   PubMed Web of Science ®Google Scholar
• Tan O, Bradshaw K, Carr BR. Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review. Menopause 2012;19:109–17
   PubMed Web of Science ®Google Scholar
• Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric 2014;17:3–9
   PubMed Web of Science ®Google Scholar
• Kingsberg S, Kellogg S, Krychman M. Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal estrogen therapy. Int J Womens Health 2010;1:105–11
   PubMedGoogle Scholar
• Gass ML, Cochrane BB, Larson JC, et al. Patterns and predictors of sexual activity among women in the hormone therapy trials of the Women's Health Initiative. Menopause 2011;18:1160–71
   PubMed Web of Science ®Google Scholar
• Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 2008;15:661–6
   PubMed Web of Science ®Google Scholar
• Nappi RE, Kokot-Kierepa M. Women's voices in the menopause: results from an international survey on vaginal atrophy. Maturitas 2010;67:233–8
   PubMed Web of Science ®Google Scholar
• Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA) - results from an international survey. Climacteric 2012;15:36–44
   PubMed Web of Science ®Google Scholar
• Panay N, Fenton A. Menopause – natural selection or modern disease? Climacteric 2015;18:1–2
   PubMed Web of Science ®Google Scholar
• Archer DF, Labrie F, Bouchard C, et al. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepaindrosterone (Prasterone). Menopause 2015;22:950–63
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer DF, Bouchard C, et al. Intravaginal dehydroepiandrosterone (Prasterone) a physiological and highly efficient treatment of vaginal atrophy. Menopause 2009;16:907–22
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer DF, Bouchard C, et al. Intravaginal dehydroepiandrosterone (DHEA, Prasterone), a highly efficient treatment of dyspareunia. Climacteric 2011;14:282–8
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer DF, Bouchard C, et al. Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study. Maturitas 2015;81:46–56
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy and of the genitourinary syndrome of menopause. Menopause 2015; in press
   Google Scholar
• World Health Organization. Sexual and reproductive health: core competencies in primary care, http://www.who.int/reproductivehealth/publications/health_systems/9789241501002/en/. 2011
   Google Scholar
• Hinchliff S, Gott M. Seeking medical help for sexual concerns in mid- and later life: a review of the literature. J Sex Res 2011;48:106–17
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer DF, Bouchard C, et al. Effect on intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 2009;16:923–31
   PubMed Web of Science ®Google Scholar
• Goldstein I. Recognizing and treating urogenital atrophy in postmenopausal women. J Womens Health (Larchmt) 2010;19:425–32
   PubMed Web of Science ®Google Scholar
• Constantine GD, Bruyniks N, Princic N, et al. Incidence of genitourinary conditions in women with a diagnosis of vulvar/vaginal atrophy. Curr Med Res Opin 2014;30:143–8
   PubMed Web of Science ®Google Scholar
• Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med 2013;10:1790–9
   PubMed Web of Science ®Google Scholar
• Simon JA, Nappi RE, Kingsberg SA, Maamari R, Brown V. Clarifying Vaginal Atrophy's Impact on Sex and Relationships (CLOSER) survey: emotional and physical impact of vaginal discomfort on North American postmenopausal women and their partners. Menopause 2014;21:137–42
   PubMed Web of Science ®Google Scholar
• Prairie BA, Wisniewski SR, Luther J, et al. Symptoms of depressed mood, disturbed sleep, and sexual problems in midlife women: cross-sectional data from the Study of Women's Health Across the Nation. J Womens Health (Larchmt) 2015;24:119–26
   PubMed Web of Science ®Google Scholar
• Prairie BA, Klein-Patel M, Lee M, Wisner KL, Balk JL. What midlife women want from gynecologists: a survey of patients in specialty and private practices. J Womens Health (Larchmt) 2014;23:513–18
   PubMed Web of Science ®Google Scholar
• Parish SJ, Nappi RE, Krychman ML, et al. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health 2013;5:437–47
   PubMedGoogle Scholar
• Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 2009;6:2133–42
   PubMed Web of Science ®Google Scholar
• Nappi RE, Kingsberg S, Maamari R, Simon J. The CLOSER (CLarifying Vaginal Atrophy's Impact On SEx and Relationships) survey: implications of vaginal discomfort in postmenopausal women and in male partners. J Sex Med 2013;10:2232–41
   PubMed Web of Science ®Google Scholar
• Kingsberg SA, Krychman ML. Resistance and barriers to local estrogen therapy in women with atrophic vaginitis. J Sex Med 2013;10:1567–74
   PubMed Web of Science ®Google Scholar
• Nappi RE, Liekens G, Brandenburg U. Attitudes, perceptions and knowledge about the vagina: the International Vagina Dialogue Survey. Contraception 2006;73:493–500
   PubMed Web of Science ®Google Scholar
• Portman DJ, Gass ML, Vulvovaginal Atrophy Terminology Consensus Conference. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Climacteric 2014;17:557–63
   PubMed Web of Science ®Google Scholar
• Perrotta C, Aznar M, Mejia R, Albert X, Ng CW. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev 2008(2):CD005131
   PubMed Web of Science ®Google Scholar
• Luthje P, Hirschberg AL, Brauner A. Estrogenic action on innate defense mechanisms in the urinary tract. Maturitas 2014;77:32–6
   PubMed Web of Science ®Google Scholar
• Nazarko L. Recurrent urinary tract infection in older women: an evidence-based approach. Br J Community Nurs 2013;18:407–8, 10–12
   PubMedGoogle Scholar
• Labrie F, Cusan L, Gomez JL, et al. Changes in serum DHEA and eleven of its metabolites during 12-month percutaneous administration of DHEA. J Steroid Biochem Mol Biol 2008;110:1–9
   PubMed Web of Science ®Google Scholar
• Labrie F, Cusan L, Gomez JL, et al. Corrigendum to: Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. J Steroid Biochem Mol Biol 2008;112:169
   Web of Science ®Google Scholar
• Labrie F, Martel C, Bérubé R, et al. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens. J Steroid Biochem Mol Biol 2013;138:359–67
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer DF, Bouchard C, et al. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. Menopause 2009;16:897–906
   PubMed Web of Science ®Google Scholar
• Labrie F, Cusan L, Gomez JL, et al. Comparable amounts of sex steroids are made outside the gonads in men and women: strong lesson for hormone therapy of prostate and breast cancer. J Steroid Biochem Mol Biol 2009;113:52–6
   PubMed Web of Science ®Google Scholar